You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest NovoPen Echo Articles
Popular NovoPen Echo Articles
Highly Recommended NovoPen Echo Articles
Send a link to this page to your friends and colleagues.
The U.S. Food and Drug Administration has granted 510(k) clearance for the NovoPen Echo®, the first insulin injection device on the market to combine half-unit dosing with a memory function to help patients manage their diabetes.
Manufacturer Novo Nordisk says the pen represents a significant milestone in insulin delivery, especially for children with diabetes and their caregivers. "It can offer caregivers increased confidence that their children are managing their diabetes appropriately away from home by allowing them to see the amount and time passed since their last dose," said Camille Lee, senior vice president, Diabetes Marketing, at Novo Nordisk.
Lee said half-unit dose increments allow for finer adjustments, which can be particularly important for children. In addition, different removable skins will be available for a customized look.
The pen, which Novo Nordisk plans to introduce to the U.S. market in 2014, will be available to patients for use with NovoLog® (insulin aspart [rDNA origin] injection) PenFill® cartridges.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.